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Introdução: As taxas de incidência de cancro da mama têm vido a aumentar na 
maioria dos países e este apresenta-se como a principal causa de morte oncológica entre as 
mulheres, apesar da diminuição na mortalidade observada nas últimas décadas por toda a 
Europa. Contudo, é ainda difícil de avaliar o quanto da redução da mortalidade pode ser 
atribuída a uma maior frequência de diagnóstico precoce, nomeadamente através de 
rastreio por mamografia, ou ao acesso a tratamentos mais eficazes. A identificação de 
grupos de países homogéneos quanto às tendências de mortalidade por cancro da mama 
pode contribuir para compreender o impacto, a nível populacional, das atuais práticas de 
diagnóstico precoce e de tratamento. 
Objectivos: Identificar padrões de tendências temporais de mortalidade por cancro da 
mama (1980-2010) através de modelos matemáticos.  
Métodos: Foram obtidos dados de mortalidade através da base de dados da 
Organização Mundial de Saúde e estimativas da população através das Nações Unidas; 
foram obtidas taxas de incidência padronizadas para a idade (população padrão mundial) 
através da base Cancer Incidence in Five Continents (CI5plus). Foram excluídos os países 
com dados disponíveis para menos de 20 anos civis entre 1980 e 2010. Foram identificados 
padrões nas tendências temporais das taxas de mortalidade padronizadas para a idade 
(todas as idades, população padrão mundial) por model-based clustering, no período em 
análise. Foram selecionados os modelos que permitiam um agrupamento mais homogéneo 
de países no que concerne ao padrão de variação da mortalidade, entre aqueles que 
apresentavam valores mais baixos do critério de informação Bayesiano (BIC), de acordo 
com a avaliação das representações gráficas das tendências em cada país. 
Resultados: Foram identificados três padrões principais. Os padrões 1 e 2 são 
caracterizados por uma estabilidade ou ligeiro aumento das taxas de mortalidade na 
primeira metade do período em análise e, na segunda metade, é observado um declínio 
marcado das tendências; no entanto, a mediana das taxas de mortalidade padronizadas 
para a idade é mais elevada nos países do padrão 1, ao longo de todo o período, e as taxas 
mais altas são atingidas mais precocemente do que no padrão 2. O padrão 3 é 
caracterizado por um rápido aumento das taxas de mortalidade até 1999, e a partir daí 
observa-se uma ligeira diminuição. 
Conclusão: Este estudo fornece um modelo geral para a descrição e interpretação de 
padrões globais de variação da mortalidade por cancro da mama na Europa, bem como uma 
base para previsões mais precisas da carga de mortalidade associada ao cancro da mama. 
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Introduction: Breast cancer incidence is increasing in most countries and is the 
leading cause of oncological death among women, despite a decline in mortality rates that 
has been observed over the last decades throughout Europe. It is still difficult to assess how 
much of the mortality reduction can be attributable to early diagnostic, namely through 
mammography screening, and to improved management. The identification of clusters of 
countries with homogeneous trends in breast cancer mortality may contribute to understand 
the impact of early detection and improved disease management at a population level.  
Objectives: To identify patterns of variation in breast cancer mortality in Europe (1980-
2010), using a model-based approach. 
Methods: Breast cancer mortality data were obtained from the World Health 
Organization (WHO) database and population estimates from the United Nations’ World 
Population Prospects; age-standardized (world standard population) incidence rates (ASIR) 
were obtained from CI5plus. Countries with data available for less than 20 calendar years 
between 1980 and 2010 were excluded. Model-based clustering was used to identify the 
patterns of time trends in age-standardized (all ages, world standard population) mortality 
rates (ASMR) in this period. The models allowing the most homogeneous grouping of the 
countries, regarding the patterns of variation in mortality rates, were selected among those 
with the lowest Bayesian Information Criterion (BIC) by visual inspection of the country-
specific trends. 
Results: Three main patterns were identified. Patterns 1 and 2 are characterized by 
stable or slightly increasing trends in ASMR in the first half of the period under analysis, and 
a clear decline is observed thereafter; however, the median of the ASMR is higher for the 
countries included in pattern 1, throughout the whole period, and the highest rates are 
achieved sooner than in pattern 2. Pattern 3 is characterised by a rapid increase in mortality 
rates until 1999, and a slow decline thereafter. 
Conclusion: This study provides a general model for the description and interpretation 
of the patterns of variation in breast cancer mortality in Europe, as well as a basis for more 
accurate predictions of the burden associated with breast cancer. 
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3.1. Morbidity and mortality burden associated with breast cancer 
Breast cancer is the malignancy most frequently diagnosed among women, both in 
developed and developing countries, with an estimated 1.4 million new cases in 2008 (23% 
of all cases of cancer among women) (1). In 2000, it was the most common tumour among 
females in low-income regions, surpassing invasive cervical cancer that had been the 
leading cancer in the previous decades (2). Incidence rates are rising in most countries, 
though a faster pace in developing countries where risk has been historically low compared 
with industrialized countries (3). 
Due to its good prognosis, breast cancer is the fifth cause of oncological death overall 
(458000 estimated deaths worldwide in 2008) (1, 4). Despite that, it is still the leading cause 
of oncological death in females worldwide (5). Approximately 59% of the deaths are 
estimated to occur in developing countries (1). 
 
Figure 1. Estimated age-standardised mortality rates (all ages), per 100,000 inhabitants 
[Source: Globocan 2008 (IARC)]. 
 
The range of mortality rates worldwide is much smaller than the range of incidence 
rates because of the improved survival rates in developed countries (higher incidence), and 
the less favourable survival observed in developing countries (1, 4). 
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Figure 2. Estimated age-standardized (World population) incidence and mortality rates, per 
100,000 inhabitants, in different regions [Source: Globocan 2008 (IARC)]. 
 
The European mean survival for breast cancer is fairly high (79.3%) (6) and has been 
increasing; this has been associated mainly with screening activities and an earlier diagnosis 
but also with improvements in the organization and delivery of care (7-10). 
Breast cancer is one of the three cancers accounting for the highest economic value 
of disability-adjusted life years (DALYs) at USD 88 billion (9.8%), surpassed only by lung and 
colon/rectum cancer, for both high-income and upper middle income countries, making 
breast cancer prevention one of the major priorities in economic and health policy strategy 
(11). 
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3.2. Determinants of breast cancer 
 
Incidence rates are highest in most of the developed countries and are lowest in less 
developed regions and in Japan (12). The international differences in both incidence and 
mortality rates indicate important differences not only in the endogenous hormonal milieu but 
also in lifestyle and environmental factors, genetic susceptibility, and mammographic 
screening activities among countries (13). 
Migrant studies indicate that environmental determinants (rather than genetic) have a 
greater impact on incidence variations (14). For instance, the risk of developing breast 
cancer in Asian-Americans is considerably higher than the one presented by native Asians, 
which are at a relatively low risk (15, 16); even in the migrating generation itself there is a 
substantial increase in risk, particularly if migration occurs early in life (14, 17). This indicates 
an important role of environmental factors in the aetiology of breast cancer (18). 
Age 
As for most cancer sites, the incidence of breast cancer increases with age, although 
up to the age of 40 the increase is steeper than the observed for other cancers, such as lung 
or colon. The incidence of breast cancer doubles about every 10 years until menopause, 
when the increase slows substantially; this relation with age has been linked to the high 
exposure to ovarian hormones from puberty to menopause (12, 13, 18). 
 
 
 
 
 
 
 
 
 
 
Figure 3. Estimated incidence rates, per 100,000 inhabitants, of breast, colorectum, stomach, 
lung and cervix uteri cancer [Source: Globocan 2008 (IARC)]. 
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Family history/genetic factors 
Family history is a well-established risk factor for breast cancer (13). A woman with a 
first degree relative who had breast cancer before the age of 50 has a risk at least twice-
higher, and the more the relative’s age of onset decreases, the higher the risk. If two first 
degree relatives develop the disease, the risk is increased by four to six times (18). 
A positive family history, developing breast cancer at a young age and bilateral disease 
are strong indicators of inherited breast cancer (19). Although two breast cancer 
susceptibility genes (BRCA1 and BRCA2) have been already identified and associated to an 
increased risk of breast cancer, genetic susceptibility accounts for less than 10% of the 
breast cancer cases in Western countries (18).  
 
Endogenous hormones 
Several studies have related serum concentration of oestradiol in postmenopausal 
women with breast cancer risk; the higher the hormonal levels, the bigger the risk [relative 
risk=2.3; 95% confidence interval (CI): 1.6 to 3.2] (20). 
Age at menarche and menopause. Reproductive factors associated with prolonged 
exposure to endogenous estrogens are among the most important risk factors for breast 
cancer; one of the first pieces of evidence suggesting this was te observation that the sooner 
a bilateral oophorectomy was performed, the greater the risk reduction (18). Both women 
who experience menarche at a younger age and the ones who stop menstruating later, are 
at higher risk of breast cancer. Thus, premenopausal women are at higher risk when 
compared to postmenopausal women of the same age (12) whether the menopause is 
natural or surgical (13). 
Childbearing. The risk of breast cancer is lower in women with at least one full-term 
pregnancy when compared to nulliparous women, and is further reduced with the increasing 
number of full-term pregnancies (13). However, the risk increases during and after the 
pregnancy due to high levels of exposure to estrogen and progesterone (21). The age of first 
pregnancy has an effect independent of the total number of pregnancies; the older a woman 
is at her ﬁrst full-term pregnancy, the higher her risk of breast cancer [relative risk of 2.0; 
(95%CI 1.1 to 3.7) for women aged 30-<35 and 2.1, (95%CI 0.7 to 6.2) at age 35 or older] 
(13, 22). 
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Breastfeeding. There is a protective effect of prolonged breastfeeding on female 
breast cancer; the relative risk of breast malignancy is reduced by 4.3% (95% CI 2.9 to 5.8) 
for each year that a woman breastfeeds (23). 
 
Exogenous hormones 
Oral contraceptives. While women who are taking combined oral contraceptives or 
who have stopped its consumption in the previous ten years have a small increase in relative 
risk of having breast cancer, ten or more years after stopping use, there is no meaningful 
excess risk (relative risk=1.01; 95%CI, 0.96 to 1.05) (24). 
Hormone replacement therapy. As with oral contraceptives, patterns of hormone 
replacement therapy (HRT) use have changed throughout the last decades. Even so, data 
suggests that there is a duration-dependent increase in breast cancer risk in HRT users, 
particularly among non-obese women (25), although the increase in risk is reversible after 
HRT ceases; there was no significant excess of breast cancer 5 or more years after 
cessation of use (relative risk=1.07; 95%CI, 0.97 to 1.18) (26). 
 
Previous benign lesions 
Severe atypical epithelial hyperplasia increases breast-cancer risk in four to five 
times; the risk is nine-fold higher in women with these changes and a first degree relative 
with history of breast cancer (18). 
 
Ionizing radiation 
Exposure to radiation is also a known risk factor for breast cancer. Women irradiated 
for Hodgkin’s disease before the age of  30 years are at higher risk for developing breast 
cancer at a younger age than average, and often before regular breast screening is 
recommended (27): relative risk of 60.6 (95% CI, 22.1 to 132) if the woman was younger 
than 16 years when she received radiation therapy; a relative risk of 4.7 (95% CI, 2.9 to 7.3) 
if she was between 16 and 29 years old, and a relative risk of 1.4 (95% CI, 1.0 to 2.1) if the 
woman was 30 years or older when receiving radiation therapy (28).  
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Lifestyle factors 
Obesity in postmenopausal women is also thought to influence breast cancer risk 
through a hormonal mechanism, once obese postmenopausal women have higher serum 
hormone concentrations via conversion of androstenedione to estrone by adipose tissue (12, 
29). 
High levels of physical activity are a protective risk factor for postmenopausal breast 
cancer, with a dose-response relationship, though with some heterogeneity in the results of 
the different studies on this topic (30). A meta-analysis of cohort studies on the association 
between recreation physical activity and postmenopausal breast cancer yielded an overall 
risk estimate of 0.97 (95%CI: 0.95 to 0.99) (30). Similar results were observed in meta-
analyses of case-control studies that considered breast cancer and postmenopausal breast 
cancer as outcome (0.90, 95%CI: 0.88 to 0.93 and 0.97, 95%CI: 0.95 to 1.00, respectively) 
(30). 
There is large evidence addressing the relation of specific food components, such as 
total fat intake and breast cancer. The report of the World Cancer Research Fund regarding 
Food, Nutrition, Physical activity and the Prevention of Cancer concluded that the evidence 
from prospective studies are inconsistent in establishing the high fat intake as a definitive risk 
factor for neither premenopausal nor postmenopausal breast cancer (30). For breast cancer 
occurring in the postmenopausal period, case-control studies consistently suggest a 
significant positive association. A meta-analysis pointed out an overall risk estimate of 1.11 
(95% CI: 1.06 to 1.16), without heterogeneity (30). However, when considering only cohort 
studies, that association was weaker and no longer significant (1.06, 95% CI: 0.99–1.14) 
(30). 
Alcohol consumption is a modifiable risk factor for breast cancer that is associated 
with a linear increase in incidence. There is an approximately 30% to 40% higher risk in 
individuals consuming at least 30 g/day of alcohol when compared to nondrinkers (31). 
 
 
3.3. Breast cancer screening 
The early detection of breast cancer may imply mammography testing, breast clinical 
examination (BCE) by a health professional and breast self-examination (BSE). Film 
mammography is the standard for breast cancer screening due to its demonstrated 
effectiveness in randomized trials (32).  
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Mammography. Either plain film or digital technologies can be used to perform 
mammography, although the shift to digital is ongoing (33). There is sufficient evidence 
showing the efficacy of screening women aged 50-69 years by mammography as the sole 
screening modality in reducing mortality from breast cancer The best estimates of the impact 
of screening mammography on breast cancer mortality range from 10% on regional mortality 
data (34), to 20% on trial results (35). Nonetheless, questions have been raised regarding 
mammography screening pertinence and efficacy both in randomized clinical trials as well as 
observational studies (36-38). 
Breast clinical examination by a health professional. There is no adequate evidence 
that there are additional effects of BCE beyond mammography on breast cancer mortality 
(32), although it may be of particular importance in less affluent countries with no sufficient 
resources for a mammography programme and where disease is often at an advance stage 
at detection (2). 
Breast self-examination. Among women who present with breast cancer clinically, 
women who perform BSE tend to have smaller tumours and improved survival than those 
who do not practice self-examination (2). However, there is adequate evidence suggesting 
that teaching BSE does not reduce breast cancer mortality (32). 
Organized programmes for mammography screening were set up for the first time in 
several Swedish districts in 1986, followed by the Netherlands, several regions of Canada 
and Finland (39). Breast cancer screening policies are not the same across the different 
countries in spite of being based in the same scientific evidence (33). 
The Council of the European Union recommends the implementation of nationwide 
screening programmes for women aged 50-69 years (40). However, breast cancer screening 
in Europe varies between organized and opportunistic, programmes managed at national 
and regional level, screening every 2 or 3 years, one or two views of the mammogram and 
the target population varies between 40 to 75 years (2, 41). 
 
Adverse effects of screening 
The two major adverse effects of screening are false-positive results and overdiagnosis 
(2). A previous North American study estimated that 23.8% of women screened had at least 
one false positive mammogram, during the 10 years of the study (42). False-positive can be 
defined as an abnormal mammogram that requires further assessment, in a woman without 
cancer (2). In addition to psychological effects such as anxiety and distress (usually transient 
effects and are not a barrier to screening), additional testing and invasive procedures, the 
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estimations of the total costs of evaluating women with false-positive results can range 
between one fourth and one third of the total costs of performing the screening (2, 32, 42, 
43).  
Another source of harm associated with screening is overdiagnosis which corresponds 
to the detection of cancers that would never have become apparent without screening and 
their detection does not contribute to mortality reduction, once these cancers do not 
represent a threat to the woman’s life (44). In these cases there are no benefits for the 
participants, and women can only experience the adverse effects of the worry associated 
with a cancer diagnosis and the complications of therapy (2). 
 
3.4. Treatment of breast cancer 
Along with the implementation of screening, there has also been an improvement in 
treatment. Randomized clinical trials have shown a considerable improvement in survival 
rates due to adjuvant chemotherapy and tamoxifen (45, 46). Beyond chemotherapy, 
radiotherapy after local excision for ductal carcinoma in situ, compared with local excision 
alone, markedly reduced the overall number of both invasive and non-invasive recurrences in 
the ipsilateral breast (at a median follow-up of 4.25 years) (47). 
Breast cancer treatment has changed considerably throughout time. In the early 
1960’s, when the first mammographic evaluations started to emerge, radical mastectomy 
was the main treatment option selected (2). Currently, in addition to surgical treatments, the 
use of adjuvant systemic treatment has substantially increased and it has become more age- 
and tumour-specific. A study performed in the Netherlands showed that not only age and 
lymph node status, were determinant in the decision of adjuvant systemic treatment, but also 
receptor status, tumour size and histologic tumour grade; however, age remained the most 
important factor when deciding about chemotherapy (48).  
At present, treatment for breast cancer often requires a combination of therapies which 
includes surgery, chemotherapy, hormonal therapy and radiation.  
 
Surgery 
Surgical treatment of breast cancer may involve breast-conserving surgery or 
mastectomy. In 2012, in the United States of America, it was estimated that most women 
with early stage breast cancer (stage I and II) were treated with breast conserving surgery 
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(57%), followed by mastectomy (36%), surgical treatments (6%); approximately 1% had no 
treatment. In contrast, among women with late stage breast cancer (stage III and IV), 13% 
undergo breast conserving surgery, 60% have mastectomy, 18% do not receive any surgery 
and 7% do not receive any treatment (49). 
Radical mastectomy was the predominant treatment option until the 1970s (2). In the 
1980s, large randomised controlled trials found no difference in overall survival between 
breast conservation therapy (lumpectomy followed by radiation) and mastectomy. Currently, 
breast conservation is considered as an acceptable surgical treatment (2, 33). Thus, most 
women diagnosed with early stage disease who undergo breast conserving surgery receive 
adjuvant treatment: among them, approximately half have radiotherapy alone and a third 
undergoes both chemo and radiation therapy. In contrast, the majority of women with late 
stage breast cancer have chemotherapy in addition to surgery and other therapies (49). 
 
Chemotherapy 
Adjuvant therapy is recommended when the risk for recurrence is intermediate or high 
(more than 10% over 10 years) (2). An overview of clinical trials on this topic showed that for 
women under 50 years old treated with chemotheraphy, an average of 2.3 months of 
relapse-free survival was gained, as well as 5.4 months of overall survival within 10 years, 
compared with no chemotherapy group (45). 
 
Hormonal therapy 
Hormone-receptor positive tumours ought to be treated with endocrine therapy (50). It 
is now known that about 5 years of adjuvant tamoxifen is more effective than shorter 
durations, even if some years of cytotoxic chemotherapy has been given. Additionally, there 
is now evidence that adjuvant tamoxifen produces substantial benefit, not only for women 
over 50 years of age but also to women under 50 (46).  
 
Radiation therapy 
Post-operative radiotherapy is often used after breast-conserving surgery but can also 
be used after mastectomy for patients with lymph node metastases or tumours in stage 3 or 
4 (2).  
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According to an overview of several trials, radiotherapy produces a reduction of about 
two-thirds in local recurrence. Breast cancer mortality was also reduced, however this effect 
on mortality is offset by an increase in vascular deaths, perhaps attributable to inadvertent 
irradiation of the coronary, carotid, or other major arteries (51). 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
4. OBJECTIVES 
  
 
 
 
  
 
 
 
 
Breast cancer is still the leading cause of oncological death among women, despite the 
decline in mortality rates that has been observed over the last decades across Europe. 
However, it is still difficult to assess how much of the mortality reduction can be attributable 
to early diagnostic through, namely by mammography screening, and in the access to more 
effective treatments. The identification of clusters of countries with homogeneous trends in 
breast cancer mortality may contribute to understand the impact of early detection and 
improved disease management at a population level. Thus, the general objective of this 
dissertation is: 
o To identify patterns in the time trends of breast cancer mortality across 
European countries using a model-based approach. 
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5.1. PATTERNS OF BREAST CANCER MORTALITY TRENDS IN EUROPE 
[Article presented in the format required by the journal for which it was submitted] 
  
 
 
 
ABSTRACT 
 
Objectives: To identify patterns of variation in breast cancer mortality in Europe (1980-
2010), using a model-based approach. 
Methods: Model-based clustering was used to identify clusters of countries with 
homogeneous variation in age-standardized mortality rates (ASMR); mortality data were 
obtained from the World Health Organization database. 
Results: Three patterns were identified. Patterns 1 and 2 are characterized by stable or 
slightly increasing trends in ASMR in the first half of the period analysed, and a clear decline 
is observed thereafter; in pattern 1 the median ASMR is higher, and the highest rates were 
achieved sooner. Pattern 3 is characterised by a rapid increase in mortality until 1999, 
declining slowly thereafter. 
Conclusion: This study provides a general model for the description and interpretation of the 
patterns of variation in breast cancer mortality in Europe, as well as a basis for more 
accurate predictions of the burden associated with breast cancer. 
 
Key-words: Breast Neoplasms; Cluster Analysis; Mortality; Early Detection of Cancer. 
  
 
 
INTRODUCTION 
 
Breast cancer is the leading cause of oncological death among women, in both 
economically developed and developing settings 1. In Europe, in the last decades the 
mortality decreased in most countries 2, along with rising incidence rates 3. 
An increasing incidence may be explained by trends towards a more frequent 
exposure to factors that contribute to a higher risk of breast cancer (e.g.: delayed 
childbearing, lower parity, use of postmenopausal hormone therapy, obesity, physical 
inactivity) 4, 5, while the widespread use of mammographic screening further contributes to 
higher incidence rates 5, 6. 
The decline in mortality rates has been attributed both to an increasing frequency of 
early diagnosis through mammography screening and access to more efficient treatments, 
including adjuvant chemotherapy or tamoxifen, besides improved radiotherapy and surgery 7-
11. The identification of clusters of countries with similar trends in breast cancer mortality may 
contribute to understand the impact, at a population level, of early detection and improved 
disease management. Previous attempts to describe breast cancer mortality patterns relied 
on criteria related to geographical 12, social, economic or cultural 13-15 characteristics. Model-
based clustering may allow a more meaningful grouping of the different settings with no a 
priori constraints, according to the mortality rates at onset of the observation period, as well 
as the magnitude and slope of its variation. 
Therefore, we aimed to identify patterns of variation in breast cancer mortality, using 
a model-based approach. 
  
 
 
METHODS 
 
Breast cancer mortality data were obtained for 40 countries from the World Health 
Organization (WHO) database updated in November 24, 2011 13. Albania, Bosnia and 
Herzegovina, Cyprus, Montenegro, The Former Yugoslav Republic of Macedonia, Serbia 
and Slovakia had data available for less than 20 calendar years between 1980 and 2010, 
and were excluded from our analyses (Figure 1). In this period, different revisions of the 
International Classification of Diseases (ICD) were used; we extracted the number of deaths, 
corresponding to the codes A054 (ICD-8), B113 (ICD-9), C50 (ICD-10). 
Mid-year estimates of the resident population were obtained from the 2010 revision of 
United Nations World Population Prospects 16. We computed age-standardized mortality 
rates (ASMR) for all ages, by the direct method, using the world standard population 17 as 
reference. 
Mixed models were used to describe the time trends in the ASMR. All models 
included random terms by country for the intercept, and slope, quadratic and cubic terms for 
calendar year. Iceland presented values three times the interquartile range above or below 
the median for at least one of the above coefficients and was excluded from further analyses 
(Figure 1). These models were used to estimate the ASMR for the years with missing data, 
between 1980 and 2010 (Appendix 1), and model-based clustering was used to identify the 
mortality patterns in this period. According to this method, the clusters are considered to be 
ellipsoidal, centred at the means, and the covariances determine their other geometric 
features. Characteristics (orientation, volume and shape) of distributions are estimated from 
the data, and can be allowed to vary between clusters, or constrained to be the same for all 
clusters. The most appropriate models were considered those allowing for the most 
homogeneous grouping the countries regarding their patterns of variation, as assessed by 
visual inspection of the country-specific trends, selected among those with the lowest 
 
 
Bayesian Information Criterion (BIC) (Appendix 2). Data analysis was conducted using data 
from 33 European countries (Figure 1), with the software R 2.14.1. 
The patterns identified through the model-based approach were further characterized 
according to gross domestic product (GDP) per capita in 1995 (the midpoint of the period 
under analysis); data was obtained from the World Bank database 18. 
Data on organized breast cancer screening activities in each country were obtained 
from published peer reviewed articles or official reports and used in the interpretation of the 
patterns, along with the trends in breast cancer incidence (Appendix 3). Age-standardized 
(world standard population) incidence rates (ASIR), and the corresponding standard errors, 
were abstracted from the Cancer Incidence in Five Continents database CI5plus, after the 
November 5, 2012 update 19, for all the years with available data in the period 1970-2002; 
data were available for 18 of the European countries eligible for model-based clustering. We 
analysed trends in incidence rates for the age groups covered by the breast cancer 
screening programmes implemented in each country, if applicable, or the age group 50 to 69 
years (defined according to European Council’s guidelines for breast cancer screening 20), as 
well as for the younger and older women than those eligible for screening. The annual 
percent change (APC), as well as significant changes in the linear trends of age-
standardized incidence and mortality rates were assessed using the software Joinpoint 
Regression Program, version 3.5.3 21. The number of joinpoints allowed was limited to a 
maximum of five (Table 2). For the United Kingdom (UK), incidence data were available only 
from Scotland and England. 
  
 
 
RESULTS 
 
We identified three main patterns of breast cancer mortality trends in Europe, 
hereafter referred to as patterns 1, 2 and 3. 
Patterns 1 and 2 are characterized by stable or slightly increasing trends in ASMR in 
the first half of the period under analysis, and a clear decline was observed thereafter; 
however, the median of the ASMR was higher for the countries included in pattern 1, 
throughout the whole period, and the highest rates were achieved sooner than in pattern 2. 
Pattern 1 comprises mostly countries from western and northern Europe, and all of them 
were high income countries [median GDP (USD): 27584, range: 9457-50600], while pattern 2 
is more heterogeneous regarding the geographical distribution and GDP [median GDP 
(USD): 15151, range: 4411-34156] (Figures 1 and 2 and Table 1). 
Pattern 3 included 11 countries with GDP lower than 5000 USD, mainly eastern and 
northern European, and four countries (Finland, France, Greece and Sweden) with GDP 
higher than 12000 USD (Figure 1). The former were characterized by the lowest median 
ASMR in 1980, which increased steeply during the first half of the period under analysis, and 
decreased thereafter, mostly after 1999 and at a slower pace than in patterns 1 and 2 (Figure 
2 and Table 1). Finland, France and Greece depicted slightly increasing trends in the first 
part of the period under study and a marked decline from that point onwards, resembling 
more closely patterns 1 and 2. However, in these countries the ASMR observed in 1980 
were among the lowest in Europe (Appendix 1). Sweden presented a downward trend 
throughout the whole period, with a steeper decrease in the second half, which is a unique 
behaviour among all the countries analysed (Appendix 1). Therefore, these four countries 
were treated separately from all other included in pattern 3, to increase the homogeneity of 
this cluster. 
 
 
Over the last three decades there was a levelling of breast cancer mortality across 
Europe. The difference between pattern 1 and pattern 3 (excluding Finland, France, Greece 
and Sweden) was about 50% in 1980, but only 10% in 2010. 
Most of the countries included in patterns 1 and 2 have organized screening 
programmes, which were initiated before 1995 in more than half of those grouped in pattern 
1 and in more than one third of those in pattern 2. Nearly two-thirds of the countries included 
in pattern 3 (excluding Finland, France, Greece and Sweden) had no organized screening 
implemented. Finland, France, Greece and Sweden had organized screening (Figure 3). 
In the age groups eligible for screening, among the countries with screening 
programmes implemented before 2002 (the last year with available date in CI5plus) there 
was a steep increase in the ASIR close to the year of screening onset, reflecting the 
increased detection of prevalent cancers, for Finland, Norway, Scotland and Sweden; these 
countries started organized screening mostly in the 1980’s and all have a participation rate of 
over 70% 22, 23. A similar increase was observed in Italy after 1995; despite having a 
screening programme implemented for the first time in 1985, only since 1996 the Italian 
Ministry of Health issued a nationally agreed protocol 24. In the remaining countries the ASIR 
increased with time in all countries considered for this analysis, regardless of the existence of 
organized screening (Table 2). 
  
 
 
DISCUSSION 
 
We identified three patterns that summarize the temporal trends in breast cancer 
mortality across European countries. Despite an overall downward trend observed in recent 
years throughout Europe, the patterns differ in the highest rates achieved and the year of 
inflection in the ASMR trends. A levelling of breast cancer mortality was observed across 
Europe over the last three decades. 
The declines in mortality rates could be explained by earlier diagnosis and mostly 
access to better management of the cases. 
Despite the observations that breast cancer incidence rates are no longer increasing 
or even declining in some settings and specific age-groups 3, 25, in all the European countries 
analysed, incidence is still increasing, or not varying significantly, in the age groups with the 
largest contribution to the overall rates. These trends are largely influenced by diagnosis and 
screening practices; estimates of excess incidence due to screening range from 11-19% 26 to 
15-25% 27, 28. Furthermore, these trends are also dependent on the frequency and changes 
of risk factors such as early menarche, delayed childbearing, lower parity, use of 
postmenopausal hormone therapy and obesity 29, 30.  Most of these risk factors are still more 
common in more affluent settings and are increasing in the less affluent 31. This is in 
accordance with the observation of the highest ASIR in the countries included in pattern 1, 
the one presenting the highest median GDP, and the lowest ASIR in the less affluent 
countries from pattern 3. 
In pattern 3 (excluding Finland, France, Greece and Sweden), although the inflection 
in the mortality rates occurred later than in the remaining countries, the ASMR peaked at 
lower values. Also, in pattern 2 the decline started later and at lower ASMR than the 
observed for pattern 1. These distinctive features suggest that the implementation of 
 
 
effective cancer control measures occurred in different moments in settings with different risk 
profiles for breast cancer. 
The best estimate of the impact of screening mammography on breast cancer 
mortality ranges from 10% on regional mortality data 32, to 20% on trial results 26. Since the 
fall in mortality in pattern 1 approached 40%, this indicates that most of the decline is due to 
improved management and treatment. Most countries included in patterns 1 and 2 and a few 
of those in pattern 3 have organized screening; however, most of the programmes were 
implemented after 1995, and in the countries where organized screening started sooner the 
expected lag of 7 to 12 years 33 between screening onset and the inflection of the mortality 
trends is not compatible with an important contribution of the programmes to the initial 
declines, although no inference is possible regarding longer term effects on mortality. 
Furthermore, these results do not exclude the potential contribution of opportunistic 
screening for the mortality reduction. In most of the countries from patterns 1 and 3 and in 
the more affluent from pattern 3, the incidence rates increased more steeply in the age-
groups eligible for screening, suggesting that mammography screening was widespread, to 
higher or lesser extent, even in the absence of screening programmes. In fact, countries with 
no programmes implemented or with lower participation rates are known to have a 
considerable volume of “opportunistic” mammography testing, namely Belgium, Czech 
Republic, France, Germany, Hungary, Italy, Malta and Switzerland 22, 34-36. Although the 
balance between benefits and risks of screening is less favourable in opportunistic 
mammography testing than in organized programmes 37, 38, the former may also have a 
favourable impact on mortality 39. 
There has been a substantial improvement in breast cancer treatments since the 
1960’s, when radical mastectomy was the predominant treatment option 40. By the late 
1980’s, in many developed countries tamoxifen and polychemotherapy were used as 
adjuvant therapy after surgical treatment for primary breast cancer; therefore, an effect in 
mortality trends should occur by early 1990’s 41, which makes the declining mortality trends 
experienced in several countries compatible with the increase in use of systemic adjuvant 
 
 
therapies. The current therapies, more effective and more age- and tumour-specific 8, 11, as 
well as the integrated organization of the provision of breast cancer care (36) contributed to a 
sustained decline in mortality rates in the last two decades, especially in countries in patterns 
1 and 2. 
Between 1980 and 2010, three different revisions of the International Classification of 
Disease (ICD) were used to code the underlying cause of death. Although changes in coding 
could induce some variation of rates, it is not likely to compromise the comparability of data 
over time, once differences between revisions are minor regarding breast cancer; only 0.9% 
more deaths are classified as breast cancer in ICD-9 than ICD-8 and 1.3% more deaths 
between ICD-10 and ICD-9 42, 43. 
The reliability of the model-based clustering was evaluated by tenfold cross validation 
44. The sample was divided in ten partitions, and each of the subsets of nine out of the ten 
partitions was used to fit ten different models (data not shown). The agreement between the 
predictions from these models and those from the model based on the complete dataset was 
moderate (kappa=0.55). This, reflects the fact that some countries depict a pattern of 
variation that does not fit so well in the main patterns, as described for Finland, France, 
Greece and Sweden, although some misclassification may be anticipated for other countries 
(e.g. Poland). This, however, does not influence the main patterns described, that reflect 
quite closely the trends in the majority of the European countries analysed. 
We used incidence data obtained from the CI5plus database to ensure some 
homogeneity of data quality. However, these data are based in a coverage of less than 15% 
of the country population from Austria, France, Germany, Italy, Netherlands, Poland, Spain 
and Switzerland 45. Since incidence data was used mainly to interpret the patterns, this has 
not compromised the validity of our findings. 
In conclusion, this study provides a general model for the description and 
interpretation of the patterns of variation in breast cancer mortality in Europe, as well as a 
basis for more accurate predictions of the burden associated with breast cancer. 
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Table 1. Characterization of the female breast cancer mortality patterns regarding the estimated age-
standardized mortality rates (direct method, world standard population), all ages (ASMR), in 1980, 
1995 and 2010, percent changes in rates in the periods 1980-1995 and 1995-2010, and highest rates 
and corresponding year observed between 1980 and 2010. 
 
  Median (percentile 25 to percentile 75) 
   Pattern 1  Pattern 2  Pattern 3* 
ASMR † 
     1980 
     1995 
     2010 
  
25.5 (24.7 to 26.5) 
25.5 (23.4 to 26.4) 
17.4 (15.9 to 18.0) 
  
19.2 (16.8 to 20.0) 
20.7 (18.2 to 21.4) 
15.1 (14.1 to 16.1) 
  
12.7 (10.7 to 14.2) 
16.0 (15.8 to 17.6) 
15.8 (14.7 to 16.1) 
Variation in ASMR (%)‡ 
     1980-1995 
     1995-2010 
  
-3.3 (-7.7 to 0.6) 
-31.3 (-32.6 to -30.4) 
  
8.0 (4.8 to 14.6) 
-23.9 (-24.9 to -22.7) 
  
33.3 (24.9 to 47.9) 
-7.2 (-12.8 to -2.2) 
ASMR § 
     Higher value observed 
     Year of higher value 
  
29.5 (27.3 to 30.0) 
1986.5 (1985.5 to 1991.5) 
  
22.1 (19.9 to 22.5) 
1993 (1991 to 1994) 
  
18.2 (16.5 to 19.6) 
1999 (1994 to 2002) 
 
ASMR – Age standardized mortality rates (world standard population) 
* The results referring to pattern 3 do not include data from Finland, France, Greece or Sweden. 
† Model estimates‡ computed from the model estimates 
§ Observed data 
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Table 2. Characterization of countries regarding trends in age-standardized incidence rates by age groups, according to patterns of trends in breast cancer 
mortality rates. 
   Age groupsb  ASIRa  Trends in ASIRa 
 Country  (years)  1988 2002  Period 1 APC (95%CI) 
Period 2 
APC (95%CI) 
Period 3 
APC (95%CI) 
Period 4 
APC (95%CI) 
Period 5 
APC (95%CI) 
Period 6 
APC (95%CI) 
Pa
tte
rn
 1
 
Denmark 
 0-49  32.0 28.4  1970-1988 1.7 (1.1 to 2.3) 
1988-2002 
-1.1 (-1.8 to -0.4)     
 50-59  210.7 264.6  1970-2002 1.9 (1.7 to 2.1)      
 60+  272.9 378.6  1970-1986 0.9 (0.4 to 1.5) 
1986-2002 
2.5 (2.0 to 3.0)     
England (UK) 
 0-49  27.1 29.5  1985-1992 1.8 (1.0 to 2.6) 
1992-2002 
0.2 (-0.2 to 0.6)     
 50-64  196.2 288.5  1985-1988 2.3 (-1.3 to 6.0) 
1988-1991 
12.6 (5.5 to 20.1) 
1991-1994 
-3.4 (-9.1 to 2.6) 
1994-2002 
2.2 (1.5 to 2.8)   
 65+  256.1 302.7  1985-2002 1.0 (0.7 to 1.2)      
Netherlands 
 0-49  29.2 39.4  1973-2002 1.1 (0.8 to 1.4)      
 50-69  203.8 319.0  1973-1991 0.8 (-0.2 to 1.9) 
1991-1995 
7.5 (-6.1 to 23.0) 
1995-2002 
-0.4 (-3.4 to 2.7)    
 70+  296.7 347.2  1973-2002 1.6 (1.0 to 2.1)      
Scotland (UK) 
 0-49  26.7 26.8  1975-2002 0.3 (0.1 to 0.5)      
 50-64  188.0 288.1  1975-1988 1.2 (0.5 to 1.9) 
1988-1991 
12.1 (-0.6 to 26.4) 
1991-2002 
0.8 (0.1 to 1.6)    
 65+  254.7 271.9  1975-2002 1.0 (0.9 to 1.2)      
Switzerland 
 0-49  23.7 26.3  1983-2002 0.6 (0.0 to 1.3)      
 50-70  221.6 298.7  1983-2002 3.1 (2.4 to 3.8)      
 70+  304.5 258.2  1983-2002 -0.9 (-1.6 to -0.3)      
Pa
tte
rn
 2
 Austria 
 0-49  22.0 24.6  1988-2002 0.9 (-0.3 to 2.0)      
 50-69  199.3 244.5  1988-2002 1.9 (1.2 to 2.7)      
 70+  317.6 356.2  1988-2002 -1.0 (-2.5 to 0.7)      
Czech Republic 
 0-44  9.9 10.1  1983-2002 0.3 (-0.3 to 0.9)      
 45-69  126.5 182.5  1983-2002 2.4 (2.1 to 2.7)      
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 70+  192.7 280.9  1983-1995 3.6 (2.8 to 4.4) 
1995-2002 
0.7 (-0.8 to 2.2)     
Germany 
 0-49  25.2 28.1  1970-2002 1.0 (0.7 to 1.4)      
 50-69  202.7 272.1  1970-1987 0.6 (-0.2 to 1.4) 
1987-2002 
2.9 (2.1 to 3.8)     
 70+  248.9 317.4  1970-2002 1.8 (1.5 to 2.1)      
Italy 
 0-49  29.1 36.5  1988-2002 2.1 (1.6 to 2.6)      
 50-69  198.3 293.4  1988-1995 2.5 (0.5 to 4.5) 
1995-1999 
7.5 (0.9 to 14.5) 
1999-2002 
-2.5 (-8.2 to 3.6)    
 70+  247.1 282.9  1988-1991 -0.7 (-2.8 to 1.6) 
1991-1995 
3.7 (1.8 to 5.8) 
1995-1999 
1.8 (0.0 to 3.5) 
1999-2002 
-2.8 (-4.4 to -1.1)   
Norway 
 0-49  21.7 23.1  1970-1996 1.3 (0.9 to 1.6) 
1996-2002 
-2.2 (-4.7 to 0.4)     
 50-69  165.5 287.1  1970-1990 0.8 (0.2 to 1.4) 
1990-2002 
5.0 (3.9 to 6.0)     
 70+  262.0 233.7  1970-1985 2.2 (1.5 to 2.9) 
1985-2002 
-0.3 (-0.8 to 0.2)     
Spain 
 0-49  20.8 26.3*  1985-2000 2.4 (1.8 to 3.1)      
 50-64  120.3 211.0*  1985-2000 3.2 (2.4 to 3.9)      
 65+  157.9 193.4*  1985-2000 2.1 (1.4 to 2.7)      
Slovenia 
 0-49  18.4 21.8  1970-2002 1.3 (0.9 to 1.6)      
 50-69  152.8 205.7  1970-2002 2.4 (2.2 to 2.7)      
 70+  197.7 259.0  1970-2002 3.1 (2.8 to 3.4)      
Pa
tte
rn
 3
 
Estonia 
 0-49  16.4 21.0  1970-2002 1.7 (1.3 to 2.1)      
 50-59  103.0 154.5  1970-2002 2.2 (1.8 to 2.6)      
 60+  105.6 170.1  1970-2002 2.9 (2.6 to 3.2)      
Finland 
 0-49  24.1 27.1  1970-1995 2.6 (2.4 to 2.9) 
1995-2002 
-0.6 (-2.0 to 0.8)     
 50-59  200.7 316.7  1970-1984 2.2 (1.5 to 2.9) 
1984-1989 
7.7 (3.7 to 11.9) 
1989-1993 
0.2 (-5.3 to 6.0) 
1993-2002 
4.4 (3.5 to 5.3)   
 60+  229.7 289.7  1970-2002 1.9 (1.6 to 2.1)      
France 
 0-49  32.5 32.1  1983-1994 2.6 (1.7 to 3.6) 
1994-2002 
-2.8 (-4.0 to -1.5)     
 50-74  229.5 361.7  1983-2002 2.9 (2.5 to 3.4)      
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 75+  240.7 277.7  1983-2002 1.2 (0.7 to 1.7)      
Latvia 
 0-49  16.6 17.3  1988-2002 1.5 (0.2 to 2.8)      
 50-69  111.0 153.8  1988-2002 3.0 (2.4 to 3.6)      
 70+  83.2 153.3  1988-2002 5.4 (3.9 to 6.9)      
Lithuania 
 0-49  16.3 16.8  1978-2002 1.3 (0.9 to 1.8)      
 50-69  95.8 136.1  1978-2002 2.9 (2.5 to 3.4)      
 70+  83.3 156.6  1978-2002 4.4 (3.8 to 5.0)      
Poland 
 0-49  18.1 19.6  1988-1995 3.4 (1.1 to 5.8) 
1995-2002 
-1.6 (-3.6 to 0.5)     
 50-69  130.5 200.2  1988-2002 3.0 (2.3 to 3.7)      
 70+  169.2 209.0  1988-1995 4.9 (1.2 to 8.8) 
1995-2002 
-1.8 (-4.6 to 1.1)     
Sweden 
 0-49  25.3 25.9  1970-2002 0.9 (0.8 to 1.1)      
 50-69  209.4 302.6  1970-1978 2.1 (1.3 to 2.8) 
1978-1986 
0.0 (-0.9 to 0.9) 
1986-1990 
8.8 (5.5 to 12.3) 
1990-1993 
-2.4 (-8.0 to 3.5) 
1993-2002 
3.0 (2.5 to 3.5)  
 70+  288.9 282.5  1970-1973 -2.4 (-6.9 to 2.5) 
1973-1979 
3.0 (1.0 to 5.0) 
1979-1984 
-2.4 (-4.9 to 0.1) 
1984-1987 
3.5 (-4.4 to 12.1) 
1987-1995 
-1.5 (-2.5 to -0.5) 
1995-2002 
1.3 (0.2 to 2.3) 
 
a ASIR – age-standardized incidence rates (world standard population) 
b Three groups were considered:  age groups covered by the organized breast cancer screening implemented in each country; age groups below the ages eligible for 
screening; age groups above the ages eligible for screening. In countries with no organized programme(s), the recommendations of the European Council’s guidelines were 
considered as reference (50-69 years) 
c Age-standardized incidence rates in the last year with data available (2000)  
 
66 
 
Figure 1. Flowchart of the model-based approach used to identify breast cancer mortality patterns. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
*Finland, France, Greece and Sweden had substantially higher GDP than the other countries included in pattern 
3, and were treated separately to increase the homogeneity of this cluster 
 
ALB=Albania; AUT=Austria; BEL=Belgium; BIH=Bosnia and Herzegovina; BGR=Bulgaria; BLR=Belarus; 
CHE=Switzerland; CYP=Cyprus; CZE=Czech Republic; DEU=Germany; DNK=Denmark; ESP=Spain; 
EST=Estonia; FIN=Finland; FRA=France; GBR=United Kingdom; GRC=Greece; HRV=Croatia; HUN=Hungary; 
IRL=Ireland; ISL=Island; ITA=Italy; LTU=Lithuania; LUX=Luxembourg; LVA=Latvia; MDA=Republic of Moldova; 
MNE=Montenegro; MKD=The Former Yugoslav Republic of Macedonia; MLT=Malta; MNE=Montenegro; 
NLD=The Netherlands; NOR=Norway; POL=Poland; PRT=Portugal; ROM=Romania; RUS=Russian Federation; 
SRB=Serbia; SVN=Slovenia; SVK=Slovakia; SWE=Sweden; UKR=Ukraine.  
33 countries 
32 countries 
40 countries 7 countries excluded because 
the data available in the WHO 
database referred to less than 20 
calendar years 
(ALB; BIH; CYP; MKD; MNE; SRB; 
SVK) 
1 country excluded - outlier (ISL) 
Pattern 1 
(8 countries) 
 
Northern Europe  
DNK; GBR; IRL 
Southern Europe  
MLT 
Western Europe  
BEL; CHE; LUX; NLD 
 
 
Median GDP in 1995 (USD): 
27584, range: 9457-50600 
Pattern 2 
(9 countries) 
 
Eastern Europe 
CZE; HUN 
Northern Europe 
NOR 
Southern Europe  
ESP; ITA; PRT; SVN 
Western Europe  
AUT; DEU 
 
Median GDP in 1995 (USD): 
15151, range: 4411-34156 
Pattern 3 
(15 countries) 
 
Eastern Europe  
BGR; BLR; MDA; POL; RUS; 
UKR 
Northern Europe  
EST; LVA; LTU 
Southern Europe  
HRV 
 
Median GDP in 1995 (USD): 
2082, range: 477-4722 
 
 
 
Northern Europe  
FIN* SWE* 
Southern Europe  
GRC*  
Western Europe 
FRA* 
 
Median GDP in 1995 (USD): 
26029, range: 12274-28726 
 
MORTALITY DATA 
Source: WHO database (1980-2010), updated in November 24, 2011  
Age-standardized: all ages; direct method; world standard population 
Eastern Europe 
(BGR; BLR; CZE; HUN; MDA; POL; ROM; RUS; SVK; UKR)  
Northern Europe 
(DNK; EST; FIN; GBR; IRL; ISL; LTU; LVA; NOR; SWE) 
Southern Europe 
(ALB; BIH; CYP; ESP; GRC; HRV; ITA; MKD; MLT; MNE; PRT; SRB; SVN) 
Western Europe 
(AUT; BEL; CHE; DEU; FRA; LUX; NLD)  
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Figure 2. Age-standardized (direct method, world standard population) breast cancer mortality rates *, 
all ages, for each pattern† identified. 
 
 
* Mean of the predictions for each of the countries included in the same pattern. 
† The results referring to pattern 3 do not include data from Finland, France, Greece or Sweden. 
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Figure 3. Proportion of countries with no organized breast cancer screening, or screening 
programmes set up in different time periods*, for each pattern identified. 
 
 
 
* We considered the existence of organized screening, regardless of its coverage or participation rates. 
† The results referring to pattern 3 do not include data from Finland, France, Greece or Sweden. 
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Appendix 1. Observed and predicted breast cancer age standardized mortality rates (direct method, World standard population), all ages. 
 
_____ Observed rates (1980-2010)     _____ Estimated rates (1980-2010) 
  
AUT=Austria; BEL=Belgium; BGR=Bulgaria; BLR=Belarus; CHE=Switzerland; CZE=Czech Republic; DEU=Germany; DNK=Denmark; ESP=Spain; 
EST=Estonia; FIN=Finland; FRA=France; GBR=United Kingdom; GRC=Greece; HRV=Croatia; HUN=Hungary; IRL=Ireland; ISL=Island; ITA=Italy; 
LTU=Lithuania; LUX=Luxembourg; LVA=Latvia; MDA=Republic of Moldova; MLT=Malta; NLD=The Netherlands; NOR=Norway; POL=Poland; 
PRT=Portugal; ROM=Romania; RUS=Russian Federation; SVN=Slovenia; SWE=Sweden; UKR=Ukraine. 
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Appendix 2. Identification of the patterns by model-based clustering. 
 
 
 
BIC – Bayesian Information Criteria (the plot depicts the BIC value multiplied by minus one) 
EII – Equal volume, equal shape, non applicable orientation; 
VII – Variable volume, equal shape, non applicable orientation; 
EEI – Equal volume, equal shape, coordinate axes orientation; 
VEI – Variable volume, equal shape, coordinate axes orientation; 
EVI – Equal volume, variable shape, coordinate axes orientation; 
VVI – Variable volume, variable shape, coordinate axes orientation; 
EEE – Equal volume, equal shape, equal orientation; 
EEV – Equal volume, equal shape, variable orientation; 
VEV – Variable volume, equal shape, variable orientation; 
VVV – Variable volume, variable shape, variable orientation. 
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Appendix 3. Characterization of countries regarding organized screening activities, by patterns of 
trends in breast cancer mortality rates. 
  Organized Screening 
 Country Year first programme started 
National coverage 
(year) 
Age group 
(years)  References 
Pa
tte
rn
 1
 
Belgium 2001 Yes 50-69  22 
Denmark 1991 No 50-59  22, 46, 47 
Ireland 2000 Yes 50-64  48-50 
Luxembourg 1992 Yes 50-69  22 
Malta - No -  34, 51 
Netherlands 1989 Yes (1997) 50-69/75a  22, 52 
Scotland (UK) 1988 Yes (1991) 50-64/70b  23 
England (UK) 1988 Yes (1995) 50-64/70c  53 
Switzerland 1999d No 50-70  22, 37, 51, 54 
Pa
tte
rn
 2
 
Austria 2008e No 50-69  55, 56 
Czech Republic 2002 Yes 45-69f  34, 36, 51 
Germany 2005 2009 50-69  22, 34, 57 
Hungary 2002g Yes 45-65  34, 58 
Italy 1985 No 45/50-69h  22, 24, 57, 59 
Norway 1996 2004 50-69  22, 60 
Portugal 1990 No 45-69  22 
Spain 1990 2000 45/50-64/69i  61 
Slovenia - No -  33 
Pa
tte
rn
 3
 
Belarus - No -  62 
Bulgaria - No -  23, 29, 32 
Croatia 2006 Yes 50-69  63, 64 
Estonia 2003 Yes 50-59  51 
Finland 1987 Yes 50-59  22, 65 
France 1989 2004 50-74  22, 66 
Greece 2004 No 40-69  22, 67 
Latvia - No -  51 
Lithuania 2006 Yes 50-69  48, 51 
Poland 2007 Yes 50-69  48, 51 
Rep. of Moldova - No -  - 
Romania - No -  51 
Russian Fed. - No -  - 
Sweden 1986 1997 40/50–69/74j  22, 48, 68 
Ukraine - No -  - 
 
a Women eligible in the Netherlands: 50-69 years; 70-75 included since 1998. 
b Women eligible in Scotland: 50-64 years; extended to 70 in 2003/04. 
c Women eligible in the United Kingdom: 50-64 years; by 2005 women aged 50-70 years were being screened. 
d A pilot programme started in Switzerland in 1993 in canton Vaud. 
e Tyrol (Austria): spontaneous mammography screening has an overall participation of 75% and was set up 
around 1993; in 2008 an organized programme started comprising the whole state. 
f Women eligible in Czech Republic: since 2010 there is no upper age limit. 
g Hungary: a pilot breast screening programme was established in 1995. 
h Women eligible in Italy: 50-69 years; several programmes include women over 70 and some invite women 45-49 
years. 
i Women eligible in Spain: 50–65 years; some regions include women up to 69 and some invite women over 45 
years. 
j Women eligible in Sweden: 100% of counties invite 50-69 years; 60-70% start at age 40 and approximately 50% 
of counties invite age group 70-74. 
 
 
  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
6. CONCLUSION 
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In conclusion, the patterns identified summarize the temporal trends in breast cancer 
mortality across European countries. We can observe an overall downward trend in recent 
years, as well as a levelling of breast cancer mortality throughout Europe over the last three 
decades 
This study provides a general model for the description and interpretation of the 
patterns of variation in breast cancer mortality throughout Europe, as well as a basis for more 
accurate predictions of the burden associated with breast cancer. 
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